Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Endocrinology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Thyroid Cancer Clinical Trials

A listing of Thyroid Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (36) clinical trials

Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

This is an, open-label, protocol designed to evaluate the activity of targeted therapy in anaplastic/undifferentiated thyroid cancer. Arm A will evaluate ATC/UTC with mutations or rearrangements detected in the ALK gene. There is no effective treatment for anaplastic thyroid cancer in the locally recurrent or metastatic setting. Ceritinib will be ...

Phase

Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors

Eligible patients will be divided into two cohorts. Cohort 1: salivary gland tumors without SOC treatment option Cohort 2: 'aggressive' thyroid cancer without SOC treatment option Both cohorts will undergo a biopsy and will begin immunotherapy plus chemotherapy. Pembrolizumab and steroid sparing taxane: docetaxel will be given every three weeks ...

Phase

Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer

PRIMARY OBJECTIVES: I. To determine the feasibility and utility of Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA) PET imaging in patients with thyroid cancer. SECONDARY OBJECTIVES: I. To assess the correlation between targeted molecular uptake of 68Ga-PSMA PET in thyroid cancer compared to areas identified as tumor by radioiodine uptake (in well-differentiated ...

Phase

Study of Apatinib in Patients With Differentiated Thyroid Cancer

The purpose of this study is to assess the efficacy and safety of apatinib in locally advanced 131I-refractory/resistant differentiated thyroid cancer

Phase

Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma

Total or near-total thyroidectomy is the primary treatment for differentiated thyroid carcinoma. Postoperatively, DTC are treated with radioiodine (131I) and thyroid stimulating hormone (TSH) suppressive levothyroxine therapy. But 5% to 20% of patients with DTC develop distant metastases; some of them become refractory to 131I therapy. Targeted therapies have been ...

Phase

Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer

To determine the efficacy and safety of intensity modulated radiation therapy combined with apatinib for inoperable or iodine refractory thyroid cancer.

Phase

A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer

This is a single-center, open-label, single armexploratory clinical trial evaluating the efficacy and safety of Apatinib in patients with local progressive/metastatic refractory thyroid cancer. The primary endpoint is objective response rate(ORR),the secondary endpoints include progression-free-survival(PFS)disease control rate(DCR);serum TgTgAbcalcitoninsafety. If any case happens as following,including withdrawing informed consent form(ICF)unbearable toxicity or ...

Phase

Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer

The aims of this trial are to evaluate the efficacy and tolerability of pemetrexed + paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer.

Phase

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Background Anti PD1/PDL1 therapies have had clinical success in a minority of unselected patients across multiple tumor types While many questions remain about optimal PD1/PDL1 staining techniques to pre-select responders, less focus is being place on how to optimize responses in a broader cohort of patients Emerging preclinical and clinical ...

Phase

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

This randomized Phase II trial will compare the progression-free survival (PFS) of sorafenib and everolimus versus sorafenib alone in patients with radioactive iodine refractory hurthle cell thyroid cancer. Prior studies have shown that the median PFS is generally around 4.5 months for sorafenib alone in this disease population. It is ...

Phase